Keyword: Mitsubishi Tanabe Pharma
Mitsubishi Tanabe’s Radicava touted its FDA approval as a win for ALS patients. But on the clinical data that backed it, the EU wants to see more.
GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.
MTPA, maker of ALS treatment Radicava, has opened up its care locator database to help patients to find healthcare and infusion centers.
Lilly sells legacy antibiotics in China; Daiichi picks a bispecific antibody in Zymeworks deal; Torrent recalls more than 1 million losartan bottles.
Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.
Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
Mitsubishi Tanabe Pharma is looking for ALS stories. Not patient stories, but rather the stories—and art and video creations—of teen caregivers.
Takeda weighs a $52 billion Shire bid, WuXi gets approval for a $900M-plus Shanghai IPO, Aslan aims to raise $86 million through an IPO on Nasdaq.
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
How do you get 100% of the payers you approach to cover a pricey new med? Mitsubishi Tanabe’s commercial chief has an idea.